Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Schleinitz

Showing results (111-120 of 168) with videos related to

Pageof 17
Sort By:
Arthritis Care & Research|July 10, 2013
Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter studyMikael Ebbo, Aurélie Grados, Eric Guedj, et al.
Blood|December 14, 2006
Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activitySilvia Ferrari, Friedrich Scheiflinger, Manfred Rieger, et al.
RMD Open|June 25, 2025
Determinants of social participation in patients living with systemic lupus erythematosus: the Psy-LUP multicentre studyCécile Manet, Marie-Anastasie Aim, Viviane Queyrel, et al.
Frontiers in Immunology|March 29, 2017
T Cell Polarization toward T<sub>H</sub>2/T<sub>FH</sub>2 and T<sub>H</sub>17/T<sub>FH</sub>17 in Patients with IgG4-Related DiseaseAurélie Grados, Mikael Ebbo, Christelle Piperoglou, et al.
Annals of the Rheumatic Diseases|December 5, 2019
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related diseaseZachary S Wallace, Ray P Naden, Suresh Chari, et al.
Nature|July 30, 2020
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axisJulien Carvelli, Olivier Demaria, Frédéric Vély, et al.
Clinical and Experimental Rheumatology|March 3, 2022
Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partnersLuca Iaccarino, Rosaria Talarico, Emanuele Bozzalla-Cassione, et al.
Autoimmunity Reviews|August 18, 2020
Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective studyPhilippe Mertz, Jean-François Kleinmann, Marc Lambert, et al.
Seminars in Arthritis and Rheumatism|June 4, 2019
Clinical presentation, treatment and outcome of IgG4-related pachymeningitis: From a national case registry and literature reviewCléa Melenotte, Julie Seguier, Mikael Ebbo, et al.
Journal of Clinical Immunology|May 4, 2010
B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the diseaseGaël Mouillot, Maryvonnick Carmagnat, Laurence Gérard, et al.
Pageof 17

Showing results (111-120 of 168) with videos related to

Sort By:
Pageof 17
Arthritis Care & Research|July 10, 2013
Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter studyMikael Ebbo, Aurélie Grados, Eric Guedj, et al.
Blood|December 14, 2006
Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activitySilvia Ferrari, Friedrich Scheiflinger, Manfred Rieger, et al.
RMD Open|June 25, 2025
Determinants of social participation in patients living with systemic lupus erythematosus: the Psy-LUP multicentre studyCécile Manet, Marie-Anastasie Aim, Viviane Queyrel, et al.
Frontiers in Immunology|March 29, 2017
T Cell Polarization toward T<sub>H</sub>2/T<sub>FH</sub>2 and T<sub>H</sub>17/T<sub>FH</sub>17 in Patients with IgG4-Related DiseaseAurélie Grados, Mikael Ebbo, Christelle Piperoglou, et al.
Annals of the Rheumatic Diseases|December 5, 2019
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related diseaseZachary S Wallace, Ray P Naden, Suresh Chari, et al.
Nature|July 30, 2020
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axisJulien Carvelli, Olivier Demaria, Frédéric Vély, et al.
Clinical and Experimental Rheumatology|March 3, 2022
Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partnersLuca Iaccarino, Rosaria Talarico, Emanuele Bozzalla-Cassione, et al.
Autoimmunity Reviews|August 18, 2020
Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective studyPhilippe Mertz, Jean-François Kleinmann, Marc Lambert, et al.
Seminars in Arthritis and Rheumatism|June 4, 2019
Clinical presentation, treatment and outcome of IgG4-related pachymeningitis: From a national case registry and literature reviewCléa Melenotte, Julie Seguier, Mikael Ebbo, et al.
Journal of Clinical Immunology|May 4, 2010
B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the diseaseGaël Mouillot, Maryvonnick Carmagnat, Laurence Gérard, et al.
Pageof 17